Priority essential medicines: identifying products. Dr Suzanne Hill September 2010

Size: px
Start display at page:

Download "Priority essential medicines: identifying products. Dr Suzanne Hill September 2010"

Transcription

1 Priority essential medicines: identifying products Dr Suzanne Hill September 2010

2 The problem looks like this

3 Robertson, Forte, Trapsida & Hill. Bull WHO 2009

4 Robertson, Forte, Trapsida & Hill. Bull WHO 2009

5 Or this

6 WHO-UNICEF Plan, 2006 Work on a global project to make paediatric medicines a priority: Add missing essential formulations to the Model list in 2007; advise on doses Develop EML for children (2007-8) Update treatment guidelines (2007-9) Develop paediatric prescribing information a formulary Develop effective methods for provision of information at the point of care Collaborate with regulatory authorities to encourage appropriate drug development and approval processes in all regulatory authorities Develop quality standards for paediatric medicines Advocate for the development of paediatric medicines by the industry Develop a system for enhancing safety monitoring of medicines in children Provide guidance on procurement and supply of paediatric medicines

7 Essential medicines for children World Health Assembly Resolution 'Make Medicines Child Size' Normative work, research needs Medicines for specific conditions Specifications for dosage forms Improving use of medicines in children National implementation

8 Preliminary consultation September 6-7 Participants from academia, procurement, donors, industry, other stakeholders Review of possible priority essential medicines for children Identify existing products that can be used Identify what is mssing Next steps

9 principles To treat: burden of disease, based on current treatment guidelines Clinical approach Weight based dosing for preference Consideration of different prescribers Strategies to enhance adherence Simplified dosing regimens Technology feasible Consideration of regulatory issues

10 Background Main burden of disease in children Neonatal infections Diarrhoea Pneumonia Malaria HIV TB

11 Global Causes of Child Deaths Black et al. Lancet, 2010 WHO. The World Health Statistics 2010 Black et al. Lancet, % of under five deaths are associated with undernutrition

12 Diarrhoea Medicine Form and strength Pack size Regimen ORS As specified (low osmolarity) 1 litre, 200 and 500 ml According to the dehydration status/guidelines Zinc Sulphate 10 or 20 mg FSOD 10 of either Once daily for 10 days NOTE : combination product would be appropriate

13 Pneumonia - Low HIV setting Category Medicine Form and strength Pack size Regimen Pneumonia (Fast breathing) Oral amoxicillin 250 or 500 mg FSOD 10 of either Twice daily, 5 days Severe pneumonia (Chest Indrawing) Oral amoxicillin 250 or 500 mg FSOD 10 of either Twice daily, 5 days Very severe pneumonia (danger signs) Oxygen, Ampicillin + gentamicin or ceftriaxone Cylinder/oxygen concentrators -500 mg or 1 G -20 mg or 40 mg/ml 500 mg or 1 G Variable Pack?? Single dose As needed Variable daily x 10 days mg/day 5 days NOTE: cotrimoxazole may be an alternative for pneumonia/fast breathing

14 Pneumonia: High HIV setting Category Medicine Form and strength Pack size Regimen Pneumonia (Fast breathing) Oral amoxicillin 250 or 500 mg FSOD 10 of either Twice daily, 5 days Severe pneumonia (Chest Indrawing) Ampicillin + gentamicin or ceftriaxone -500 mg or 1 G -20 mg or 40 mg/ml 500 mg or 1 G Pack?? Single dose Variable daily x 10 days mg/day 5 days Very severe pneumonia (danger signs) Oxygen, Ampicillin + gentamicin or ceftriaxone Cylinder/oxygen concentrators -500 mg or 1 G -20 mg or 40 mg/ml 500 mg or 1 G Variable Pack?? Single dose As needed Variable daily x 10 days mg/day 5 days

15 Malaria Category Medicine Form and strength Pack size Regimen Malaria (uncomplicated) Artemeter +Lumefantrine (FDC) Artesunate + amodiaquine (FDC) Variable FSOD see treatment guideline For 3 day treatment 6x1 & 6x2 (30 blisters per box) 3 (25 blisters per box) Daily or twice daily x 3 days Malaria (severe or pre-referral) Artesunate Quinine hydrochloride 60 mg Injection 152 mg/ml injection?50/pack 100 ampoules/pack 2.4 mg/kg iv, 3 doses, then daily; 20mg infusion then 10mg/kg 8 hrly Artesunate rectal 50, 100, 200 mg Suppositories 6 per pack 10 mg/kg dose

16 HIV Category Medicine Form and strength Pack size Regimen HIV treatment AZT+3TC+NVP (< 3 years) AZT+3TC+EFV (>3 years) mg+50 mg FDC tablet, scored the 2nd one not available 30 days Once or twice daily HIV - Prophylaxis Isoniazid Cotrimoxazole 100 mg TMP 80+SMX 400mg; TMP 20+SMX 100 mg 30 days 30 days 10 mg/kg mg TMP /day age related doses

17 HIV ARV Prophylaxis Category Medicine Form and strength Pack size Regimen Breastfeeding population NVP 15mg once daily (10mg for low birth weight) Strength?? Form?? 30 days Variable according to weight and age Daily from birth until one week after all exposure to breastmilk Non breastfeeding population AZT or NVP 15mg twice daily or 15 mg once daily Strength?? Form?? 15 days? 45 days Variable according to weight and age For 4-6 weeks All exposed infants AZT or NVP 15mg twice daily or 15 mg once daily Strength?? Form?? 15 days? 45 days Variable according to weight and age For 4-6 weeks

18 Neonates Category Medicine Form and strength Pack size Regimen Neonatal sepsis Ampicillin + gentamicin or ceftriaxone Procaine penicillin? -500 mg or 1 G - 20 mg /ml 500 mg or 1 G?? Single dose Single dose -50 mg/kg x2 doses for 1 week and x3 doses for 2-4 wk mg/kg/day in 0-6 days and mg/kg in 7-59 days x mg/kg /day -40,000-60,000 units/kg/day Neonatal care Chlorhexidine Vitamin K Caffeine citrate 4% solution 1 mg/1 ml, 10 mg/ml 20mg/ml injection or oral liquid?? 500 ml Variable Variable Topical application mg x 1 at birth; 5mg/kg/day

19 Miscellaneous Category Medicine Form and strength Pack size Regimen Child survival Vitamin A 100,000 units capsule variable 100,000 units every 6 months Pain Paracetamol Variable FSOD 5-10 days supply 15 mg/kg 4-6 hours Morphine 10 mg oral dosage form 5 days Variable every 6 hours 10m/ml injection

20 TB Category Medicine Form and strength Pack size Regimen Treatment intensive phase, 2 months Isoniazid Rifampicin Pyrazinamide ethambutol 4 component FDC, flexible oral solid dosage form containing days In this does, weight based dosing, once daily Or product with same ratio Treatment, continuation phase, 4 months Isoniazid Rifampicin Pyrazinamide 3 component FDC, flexible oral solid dosage form containing Or 2 component FDC, flexible oral solid dosage form

21 FULL ASSET PROFILE: Amoxicillin Attribute Worst case BASE CASE Best case Comment Summary Profile Description Objective / Rationale Develop a dispersible amoxicillin product for pediatric patients in the developing world target age range? Dosing Regimen Twice daily Weight based dosing: 2-4kg 0.5 x 250mg tablet bd 5-9kg 1 x 250mg tablet bd 10-20kg 1 x 500mg tablet bd 21-30kg 2 x 500mg tablet bd Presentation (form and pack size) sachet? Taste-masked, dispersible tablet. Pack size 10 meltaway formulation flavor preferences? Can it be given in breast milk? Strength 250mg or 500 mg Both in packs of 10 Duration of Therapy Quality Standard Scoring 5 days SRA approval - WHO PQ, US FDA, or equivalent yes Packaging Blister packs? Any labeling requirements? Stability/shelf life Estimate Year of Launch Selling Price XX XXX XX Royalties 2 years minimum, zone 4 stability, store at or below X C 3 or more years no cold chain requirements *Prices taken from WHO/UNICEF Sources and prices of selected medicines for children Median price (USD) per dose, unless otherwise stated. XXX Current amoxicillin price*: 250 mg dispersible 0,022; 500 mg capsule 0,032; 250 mg capsule 0,018 will developing company get to charge "reasonable" or get other market advantage?

22 Weight based dosing Examples Antiretrovirals First line treatments for TB Amoxicillin

23 Amoxicillin/ cotrimoxazole weight (kg) amoxicillin bd (at least 50mg per day) cotrimoxazole bd (TMP at least 8mg/day) 250 total mg/kg per day 500 total mg/kg per day (TMP) total mg/kg per day (TMP) total per day tabs per dose tabs per dose tabs per dose tabs per dose

24 Strategies to enhance adherence Packaging and labelling Artemether-lumefantrine What pack size for long term treatments? TB, HIV What approach will work for community based administration of antibiotics?

25 Technology/dosage form Oral versus not Stable, long shelf life Avoiding liquids Flexible oral solid dosage form Simplified dosing schedules, weight based dosing

26 Regulatory questions - product Does a change of doing regimen need a change of label? Amoxicillin? What about pack size? 10 versus 21? What about different FDCs without an innovator? HIV, TB?

27 'Sure' ORS But with a smaller sachet and flavour, pack of 10 Zinc 20mg scored dispersible- with ORS ACT(s) Dispersible / FOSD dose optimised see WHO guidelines Artesunate Rectal, and injection (but better) HIV FDC (s) - see WHO guidelines Nevirapine, zidovudine Amoxicillin dispersible, scored 250 and 500, pack of 10 Oxygen TB FDCs next slide Analgesics paracetamol ( dispersible), morphine Vitamin A 100,000 IU

28 Work needed TB FDC correct component strength** Artesunate - injection and rectal mg dose range (10mg/kg) Caffeine citrate standard product, market readiness - 20mg/ml, liquid and injection Chlorhexidine solution, 4% regulatory pathway and patient pack Isoniazid / cotrimoxazole product strength not yet known for prophylaxis (HIV co pack?)

29 Problems -TB rifampicin: 15 mg/kg/d (10 to 20 mg/kg/day) isoniazid: 10 mg/kg/d (10 to 15 mg/kg/day) pyrazinamide: 35 mg/kg/d (30 to 40 mg/kg/day) ethambutol: 20 mg/kg/d (15 mg to 25 mg/kg/d) WANTED - Fixed Dose Combination (FDC) containing rifampicin 250 mg, isoniazid 150 mg, pyrazinamide 400 mg, and ethambutol 250 mg Dose: 0.5 to 2.0 'tablets' per day, 5-30 kg

30 Problems - TB

31 Solutions needed

32 Clinical evidence needed Optimised dosing regimens for Vitamin K? Gentamicin Ampicillin Procaine penicillin Ceftriaxone

33 Priority essential medicines for children Priority Essential Necessary

34 Priority essential medicines for children Necessary Essential Priority

35 Where is my essential medicine?

Medicines recommended to prevent and manage the priority diseases at the community and health facility level

Medicines recommended to prevent and manage the priority diseases at the community and health facility level s recommended to prevent and manage the priority diseases at the community and health facility level Shamim Qazi Department of Child and Adolescent Health and Development Global Causes of Child Deaths

More information

Sources and Prices of Medicines for Children.

Sources and Prices of Medicines for Children. Sources and Prices of Medicines for Children. Consultation on Priority Essential Medicines for Child Survival 6th-7th September, 2010 Copenhagen, Denmark 1 Sources and Prices of Selected Medicines for

More information

A Call to Action Children The missing face of AIDS

A Call to Action Children The missing face of AIDS A Call to Action Children The missing face of AIDS OVERVIEW OF PRESENTATION Introduction : lessons learnt Availability ; implications of making paediatric formulations available Remaining challenges in

More information

Rationalization of the Pediatric Antiretroviral Formulary to Optimize Pediatric Antiretroviral Treatment in Malawi

Rationalization of the Pediatric Antiretroviral Formulary to Optimize Pediatric Antiretroviral Treatment in Malawi Rationalization of the Pediatric Antiretroviral Formulary to Optimize Pediatric Antiretroviral Treatment in Malawi Presented by: Nandita Sugandhi M.D. 6 th International Workshop on HIV Pediatrics July

More information

IATT Optimal List of Paediatric ARV Formulations: Background and Update

IATT Optimal List of Paediatric ARV Formulations: Background and Update IATT Optimal List of Paediatric ARV Formulations: Background and Update Nandita Sugandhi Clinton Health Access Initiative, USA PADO/IATT Update for ARV Manufacturers October 19, 2015 Overview Rationale

More information

Update on the IATT Paediatric Formulary. WHO/UNAIDS Consultation with manufacturers March 2015, Geneva, Switzerland

Update on the IATT Paediatric Formulary. WHO/UNAIDS Consultation with manufacturers March 2015, Geneva, Switzerland Update on the IATT Paediatric Formulary WHO/UNAIDS Consultation with manufacturers March 2015, Geneva, Switzerland Summary The Challenge Rationale for Paediatric ARV Formulary Optimization 2015 Revised

More information

The International Pharmacopoeia - Overview

The International Pharmacopoeia - Overview The International Pharmacopoeia - Overview Caroline Mendy - Technical Officer Quality Assurance and Safety: Medicines World Health Organization 1 The International Pharmacopoeia Ph. Int. Scope WHO Consultative

More information

Il programma dei farmaci essenziali dell OMS, la nuova lista marzo Suzanne Hill Department of Medicines Policy and Standards WHO

Il programma dei farmaci essenziali dell OMS, la nuova lista marzo Suzanne Hill Department of Medicines Policy and Standards WHO Il programma dei farmaci essenziali dell OMS, la nuova lista marzo 2007 Suzanne Hill Department of Medicines Policy and Standards WHO Essential medicines 30 years on Outline A review of 30 years of essential

More information

List of Optimal Paediatric Formulations. Marianne Gauval (CHAI) IAS-ILF Round table Geneva, Switzerland 26 November 2013

List of Optimal Paediatric Formulations. Marianne Gauval (CHAI) IAS-ILF Round table Geneva, Switzerland 26 November 2013 List of Optimal Paediatric Formulations Marianne Gauval (CHAI) IAS-ILF Round table Geneva, Switzerland 26 November 2013 1 History of development of treatment options for children Adult tablets Syrups and

More information

Application for Inclusion of Lopinavir /Ritonavir Oral Granules (LPV/r) Formulation on WHO Model List of Essential Medicines for Children

Application for Inclusion of Lopinavir /Ritonavir Oral Granules (LPV/r) Formulation on WHO Model List of Essential Medicines for Children Application for Inclusion of Lopinavir /Ritonavir Oral Granules (LPV/r) Formulation on WHO Model List of Essential Medicines for Children Table of Contents 1. Summary statement of proposal for inclusion...

More information

Strategies to Control Pneumonia and Diarrhoea: Tackling the deadliest diseases for the world s poorest children

Strategies to Control Pneumonia and Diarrhoea: Tackling the deadliest diseases for the world s poorest children Strategies to Control Pneumonia and Diarrhoea: Tackling the deadliest diseases for the world s poorest children Dr. Mark W. Young Senior Health Specialist UNICEF Programme Division New York September 24,

More information

Invitation to Manufacturers 16 August 2017

Invitation to Manufacturers 16 August 2017 Invitation to Manufacturers 16 August 2017 Manufacturers of Antiretroviral (HIV/AIDS), Antihepatitis B and C, Antituberculosis and Antimalarial medicines Are Invited to Submit An Expression of Interest

More information

CURRENT WORK PLAN New monographs for inclusion in The International Pharmacopoeia and revision of related monographs

CURRENT WORK PLAN New monographs for inclusion in The International Pharmacopoeia and revision of related monographs page 1 CURRENT WORK PLAN New monographs for inclusion in The International Pharmacopoeia and revision of related monographs 2011 The following categories are included in this work programme: 1. Medicines

More information

Paediatric ART Working Group. guideline review meetings

Paediatric ART Working Group. guideline review meetings Paediatric ART Working Group Report back from Sept 2009 and Dec 2009 ART guideline review meetings Paediatric ARV working group priorities Continue to emphasise need for scored adult FDCs this avoids need

More information

The pathway to better medicines for children

The pathway to better medicines for children The pathway to better medicines for children As the World Health Organization counts down to 2015 and the Millennium Development Goal to reduce under five-year-old mortality by two-thirds, we reflect on

More information

Existing and most needed paediatric ARV formulations

Existing and most needed paediatric ARV formulations Existing and most needed paediatric ARV formulations Martina Penazzato Paediatric HIV advisor WHO HIV Department, Geneva Mach 7th 2016 Paediatric coverage still lags behind 45 40 35 30 25 20 15 10 5 0

More information

JOINT WHO/UNAIDS/UNICEF STATEMENT ON USE OF COTRIMOXAZOLE AS PROPHYLAXIS IN HIV EXPOSED AND HIV INFECTED CHILDREN

JOINT WHO/UNAIDS/UNICEF STATEMENT ON USE OF COTRIMOXAZOLE AS PROPHYLAXIS IN HIV EXPOSED AND HIV INFECTED CHILDREN JOINT WHO/UNAIDS/UNICEF STATEMENT ON USE OF COTRIMOXAZOLE AS PROPHYLAXIS IN HIV EXPOSED AND HIV INFECTED CHILDREN WHO, UNAIDS and UNICEF, guided by recent evidence, have agreed to modify as an interim

More information

Guidelines for management of suspected sepsis in young infants where referral is not possible

Guidelines for management of suspected sepsis in young infants where referral is not possible Guidelines for management of suspected sepsis in young infants where referral is not possible Kenya Paediatrics Association Conference, 26-29 April 2016, Eldoret Kenya 1 Kenya Paediatrics Association Conference,

More information

CHILDREN S MEDICINES IN UGANDA

CHILDREN S MEDICINES IN UGANDA Medicines for Children CHILDREN S MEDICINES IN UGANDA An investigation into availability and factors impacting access INTRODUCTION The continuous availability of affordable medicines for children is necessary

More information

The Global Accelerator for Paediatric Formulations (GAP-f) Ensuring children have accelerated access to optimal drug formulations

The Global Accelerator for Paediatric Formulations (GAP-f) Ensuring children have accelerated access to optimal drug formulations Slide 1 The Global Accelerator for Paediatric Formulations (GAP-f) Ensuring children have accelerated access to optimal drug formulations Sébastien Morin (International AIDS Society, Switzerland) 9 th

More information

Management of Multidrug- Resistant TB in Children. Jennifer Furin, MD., PhD. Sentinel Project, Director of Capacity Building

Management of Multidrug- Resistant TB in Children. Jennifer Furin, MD., PhD. Sentinel Project, Director of Capacity Building Management of Multidrug- Resistant TB in Children Jennifer Furin, MD., PhD. Sentinel Project, Director of Capacity Building Objectives To review data on best practices for diagnosis, treatment and prevention

More information

What essential medicines for children are on the shelf?

What essential medicines for children are on the shelf? Jane Robertson et al. Availability of essential children s medicines What essential medicines for children are on the shelf? Jane Robertson, a Gilles Forte, b Jean-Marie Trapsida c & Suzanne Hill b a University

More information

Clinton Foundation HIV/AIDS Initiative ARV Procurement Forecast Tool Version 1.4 March, User s Manual

Clinton Foundation HIV/AIDS Initiative ARV Procurement Forecast Tool Version 1.4 March, User s Manual Clinton Foundation HIV/AIDS Initiative ARV Procurement Forecast Tool Version 1.4 March, 2005 User s Manual Index 1. Overview 2. Scale-Up Assumptions 3. Procurement Assumptions 4. Clinical Assumptions 5.

More information

Integrated Community Case Management (iccm) and the role of pneumonia diagnostic tools

Integrated Community Case Management (iccm) and the role of pneumonia diagnostic tools Integrated Community Case Management (iccm) and the role of pneumonia diagnostic tools Theresa Diaz MD MPH Senior Health Advisor Health Section UNICEF, NY (on behalf of Mark Young) Strong need for community-based

More information

Frequently Asked Questions on Zinc and Suggested Responses

Frequently Asked Questions on Zinc and Suggested Responses Last edited: September 27, 2012 Zinc Treatment of Childhood Diarrhea Frequently Asked Questions Diarrhoea still remains a leading cause of morbidity and mortality in developing countries. Every year more

More information

Fixed Dose Combination a Simplified Approach to Pediatric Antiretroviral Treatment

Fixed Dose Combination a Simplified Approach to Pediatric Antiretroviral Treatment Fixed Dose Combination a Simplified Approach to Pediatric Antiretroviral Treatment Dr. David Pugatch Clinton Foundation Phnom Penh, Cambodia February, 2007 Lecture Goals To introduce and define fixed dose

More information

Dr. Rai Muhammad Asghar Associate Professor of Pediatrics Benazir Bhutto Hospital Rawalpindi

Dr. Rai Muhammad Asghar Associate Professor of Pediatrics Benazir Bhutto Hospital Rawalpindi Dr. Rai Muhammad Asghar Associate Professor of Pediatrics Benazir Bhutto Hospital Rawalpindi MANAGEMENT OF THE CHILD WITH COUGH OR DIFFICULT BREATHING Global Burden * Commonest cause of death * 2 million

More information

Pediatric ARV Working Group Dosing Recommendations

Pediatric ARV Working Group Dosing Recommendations Pediatric ARV Working Group Dosing Recommendations Overall Goals To develop pediatric weight band dosing for ARVs that would simplify dosing and produce therapeutic drug exposure Recommend dosing strengths

More information

Department of Pediatrics RGH Rawalpindi Medical College

Department of Pediatrics RGH Rawalpindi Medical College Department of Pediatrics RGH Rawalpindi Medical College COUGH OR DIFFICULT BREATING Dr. Rai Muhammad Asghar Associate Professor of Pediatrics department RGH Rawalpindi MANAGEMENT OF THE CHILD WITH COUGH

More information

Adherence to case management guidelines of IMCI by health care workers in Tshwane

Adherence to case management guidelines of IMCI by health care workers in Tshwane Adherence to case management guidelines of IMCI by health care workers in Tshwane S Afr J Child Health 2015;9(3):89-92. DOI:10.7196/SAJCH.7959 Mphele Mulaudzi UPdate 4 March 2016, Menlyn Introduction Integrated

More information

Child Health Services Tanzania Service Provision Assessment (TSPA)

Child Health Services Tanzania Service Provision Assessment (TSPA) Child Health Services 2014-15 Tanzania Service Provision Assessment (TSPA) Background of Child Health (2010 TDHS) Availability of Services Service Readiness Management Practices and Training Observations

More information

MMV s Access & Product Management Strategy

MMV s Access & Product Management Strategy MMV s Access & Product Management Strategy Siem Reap, Cambodia 24-26 February 2015 George Jagoe, EVP, Access & Product Mgmt Defeating Malaria Together OUR MISSION to reduce the burden of malaria in disease-endemic

More information

INTEGRATED MANAGEMENT OF CHILDHOOD ILLNESS FOR HIGH HIV SETTINGS

INTEGRATED MANAGEMENT OF CHILDHOOD ILLNESS FOR HIGH HIV SETTINGS Department of Child and Adolescent Health and Development (CAH) INTEGRATED MANAGEMENT OF CHILDHOOD ILLNESS FOR HIGH HIV SETTINGS CHILD AGE 2 MONTHS UP TO 5 YEARS ASSESS AND CLASSIFY THE SICK CHILD Assess,

More information

Babies 1500g. Caffeine citrate. Sodium Acid Phosphate (1mmol/ml) Ferrous Fumarate (Galfer 140mg/5ml) Infloran. Abidec BMF

Babies 1500g. Caffeine citrate. Sodium Acid Phosphate (1mmol/ml) Ferrous Fumarate (Galfer 140mg/5ml) Infloran. Abidec BMF Babies 1500g Infloran Caffeine citrate BMF Sodium Acid Phosphate (1mmol/ml) Abidec Ferrous Fumarate (Galfer 140mg/5ml) Dose Half capsule BD 10mg/kg once daily (write as caffeine citrate) 2% BMF each feed

More information

Nutrition Procurement Overview

Nutrition Procurement Overview Nutrition Procurement Overview RUTF Pre-tender Industry Consulation Copenhagen, 11-13 June 2018 Click to edit Master subtitle style Supply Division Structure (2018-2021) Director Deputy Director Programme

More information

NEW PNEUMONIA CASE MANAGEMENT GUIDELINES. By Andolo Miheso,Christine Wambugu, Sophie Ngugi, Warfa Osman (NCAHU MOH) & Ambrose Agweyu (KWT)

NEW PNEUMONIA CASE MANAGEMENT GUIDELINES. By Andolo Miheso,Christine Wambugu, Sophie Ngugi, Warfa Osman (NCAHU MOH) & Ambrose Agweyu (KWT) NEW PNEUMONIA CASE MANAGEMENT GUIDELINES By Andolo Miheso,Christine Wambugu, Sophie Ngugi, Warfa Osman (NCAHU MOH) & Ambrose Agweyu (KWT) Outline of the presentation: Overview of Child Health situation

More information

Challenges along the paediatric ARV pipeline Summary: IAS-ILF Industry Roundtable on Paediatric ARVs. Presented by Shaffiq Essajee (CHAI, USA)

Challenges along the paediatric ARV pipeline Summary: IAS-ILF Industry Roundtable on Paediatric ARVs. Presented by Shaffiq Essajee (CHAI, USA) Challenges along the paediatric ARV pipeline Summary: IAS-ILF Industry Roundtable on Paediatric ARVs Presented by Shaffiq Essajee (CHAI, USA) Optimize paediatric ARVs and shape the market PADO New drugs,

More information

MATERNAL, NEWBORN, AND CHILD HEALTH

MATERNAL, NEWBORN, AND CHILD HEALTH MATERNAL, NEWBORN, AND CHILD HEALTH SESSION OBJECTIVES Introduction to GHSC-PSM Maternal, Newborn, and Child Health (MNCH) strategy and priorities Defining MNCH commodities Overview of historical and current

More information

UNICEF/Malawi/2015/Schermbrucker. policy brief 2016 UPDATE

UNICEF/Malawi/2015/Schermbrucker. policy brief 2016 UPDATE UNICEF/Malawi/2015/Schermbrucker policy brief IATT PAEDIATRIC ARV FORMULARY AND LIMITED-USE LIST: 2016 UPDATE BACKGROUND Delivery of antiretroviral treatment (ART) to children living with HIV is associated

More information

Update on global guidelines. and emerging issues on perinatal HIV prevention. WHO 2013 Consolidated ARV Guidelines

Update on global guidelines. and emerging issues on perinatal HIV prevention. WHO 2013 Consolidated ARV Guidelines WHO 2013 Consolidated ARV Guidelines Update on global guidelines H I V / A I D S DEPARTMENT and emerging issues on perinatal HIV prevention Children & HIV, St. Petersburg, Russia Sept 25-26, 2014 Dr. Nathan

More information

CADO/PADO: Update on 2015 WHO Consolidated guidelines Towards Treat All in the context of SDGs

CADO/PADO: Update on 2015 WHO Consolidated guidelines Towards Treat All in the context of SDGs CADO/PADO: Update on 2015 WHO Consolidated guidelines Towards Treat All in the context of SDGs Meg Doherty, Treatment and Care Coordinator WHO HQ Outline What s new in ARV Guidelines Drug optimisation

More information

Overview of UNICEF engagement in health & supply. Supply Division, 27 September 2010

Overview of UNICEF engagement in health & supply. Supply Division, 27 September 2010 Overview of UNICEF engagement in health & supply Supply Division, 27 September 2010 Presentation outline Reaching MDGs with equity Priority interventions Introduction to UNICEF Supply Divisions work The

More information

Have new initiatives to improve availability made a difference?

Have new initiatives to improve availability made a difference? Have new initiatives to improve availability made a difference? Evidence from the ARV field on changes in the pediatric medicines market Brenda Waning WHO/UNITAID 5 November, 2010 American Society of Tropical

More information

Antimalarials in the WHO Essential Drugs List for Children Reviewer No.1

Antimalarials in the WHO Essential Drugs List for Children Reviewer No.1 Antimalarials in the WHO Essential Drugs List for Children Reviewer No.1 Part I: Evaluation of the current list Proposed grouping from the March 2007 meeting 6.5.3 Antimalarial medicines 6.5.3.1 For curative

More information

Toolkit on monitoring health systems strengthening MEDICAL PRODUCTS, VACCINES AND TECHNOLOGIES

Toolkit on monitoring health systems strengthening MEDICAL PRODUCTS, VACCINES AND TECHNOLOGIES Toolkit on monitoring health systems strengthening MEDICAL PRODUCTS, VACCINES AND TECHNOLOGIES June 2008 Table of contents 1. Introduction... 2 2. Data sources... 2 Facility reporting systems...3 Key informant

More information

INITIATING ART IN CHILDREN: Follow the six steps

INITIATING ART IN CHILDREN: Follow the six steps INITIATING ART IN CHILDREN: Follow the six steps STEP 1: DECIDE IF THE CHILD HAS CONFIRMED HIV INFECTION Child < 18 months: HIV infection is confirmed if the PCR is positive and the VL is more than 10,000

More information

ANTIRETROVIRAL (ART) DRUG INFORMATION FOR HEALTH CARE PROFESSIONAL

ANTIRETROVIRAL (ART) DRUG INFORMATION FOR HEALTH CARE PROFESSIONAL ZIDOVUDINE (AZT, Retrovir ) Benefits of zidovudine: Zidovudine (ZDV) is an antiretroviral drug that slows the growth of the HIV virus. It has shown in a large randomized, multicentre study to decrease

More information

Essential Medicines: update on policies and standards

Essential Medicines: update on policies and standards Essential Medicines: update on policies and standards Jane Robertson Technical Officer Health Technologies and Pharmaceuticals (HTP) WHO Regional Office for Europe Pharmaceutical sector is complex R&D

More information

TOWARDS ELIMINATION OF MOTHER TO CHILD TRANSMISSION OF HIV

TOWARDS ELIMINATION OF MOTHER TO CHILD TRANSMISSION OF HIV TOWARDS ELIMINATION OF MOTHER TO CHILD TRANSMISSION OF HIV Gladwel Muthoni KPA Conference 24 th April, 2018 OUTLINE Burden of HIV in PMTCT Mechanism and timing of Mother to Child Transmission (MTCT) Four

More information

TB/HIV Monitoring & Advocacy Project Interview Tool

TB/HIV Monitoring & Advocacy Project Interview Tool TB/HIV Monitoring & Advocacy Project Interview Tool This interview tool is based upon the Interim Policy on Collaborative TB/HIV Activities of the World Health Organization. 1 It is designed to help you

More information

International initiatives on extemporaneous dispensing

International initiatives on extemporaneous dispensing Partners meeting WHO, Geneva 21 22 November 2011 International initiatives on extemporaneous dispensing Tony Nunn and Mark Turner UK Medicines for Children Research Network University of Liverpool Industry

More information

1. PROCEDURE FOR THIS INVITATION TO EOI 2. APIS INCLUDED IN THE 14TH INVITATION. Guidance Document 11 April 2017

1. PROCEDURE FOR THIS INVITATION TO EOI 2. APIS INCLUDED IN THE 14TH INVITATION. Guidance Document 11 April 2017 To support national and global efforts to increase access to and the affordability of care and treatment of HIV/AIDS, hepatitis B and C, tuberculosis, malaria, neglected tropical diseases, influenza, diarrhoea

More information

Figure S1: Overview of PMTCT Options A and B. Prevention of Mother to Child HIV Transmission (PMTCT)

Figure S1: Overview of PMTCT Options A and B. Prevention of Mother to Child HIV Transmission (PMTCT) Figure S1: Overview of PMTCT Options A and B Prevention of Mother to Child HIV Transmission (PMTCT) Option A: combined Antiretroviral therapy (ART) for all women meeting WHO 2010 criteria for initiation

More information

18 July 2009 The 1st International Workshop on HIV Pediatrics Cape Town, South Africa

18 July 2009 The 1st International Workshop on HIV Pediatrics Cape Town, South Africa A Novel Pediatric Fixed-Dose Combination (FDC) of Zidovudine (ZDV), Lamivudine (3TC), Nevirapine (NVP): Pharmacokinetics and Safety in HIV-Infected Thai Children 18 July 2009 The 1st International Workshop

More information

The New National Guidelines. Feeding in the Context of HIV. Dr. Godfrey Esiru; National PMTCT Coordinator

The New National Guidelines. Feeding in the Context of HIV. Dr. Godfrey Esiru; National PMTCT Coordinator The New National Guidelines (2010) for PMTCT and Infant Feeding in the Context of HIV Dr. Godfrey Esiru; National PMTCT Coordinator Presentation outline Evolution of the PMTCT guidelines in Uganda Rational

More information

Innovation, Access and Use Department of Essential Medicines and Health Products WHO

Innovation, Access and Use Department of Essential Medicines and Health Products WHO MARKETS FOR QUALITY-ASSURED PRODUCTS Sarah Garner and Francisco Blanco Innovation, Access and Use Department of Essential Medicines and Health Products WHO 1 Objectives Indicate market needs for medicines

More information

Q&A for submission of applications for prequalification of Zinc Sulfate tablets and Zinc Sulfate oral liquid (solution)

Q&A for submission of applications for prequalification of Zinc Sulfate tablets and Zinc Sulfate oral liquid (solution) Q&A for submission of applications for prequalification of Zinc Sulfate tablets and Zinc Sulfate oral liquid (solution) This document should not be treated as a comprehensive guideline; it serves as a

More information

An innovative mechanism for scaling up access to medicines and diagnostics for HIV/AIDS, tuberculosis and malaria

An innovative mechanism for scaling up access to medicines and diagnostics for HIV/AIDS, tuberculosis and malaria UNITAID An innovative mechanism for scaling up access to medicines and diagnostics for HIV/AIDS, tuberculosis and malaria ECOSOC Annual Ministerial Review (Regional Ministerial Meeting on Financing Strategies

More information

Paediatric ART: eligibility criteria and first line regimens. (revised) Dave le Roux 13 August 2016

Paediatric ART: eligibility criteria and first line regimens. (revised) Dave le Roux 13 August 2016 Paediatric ART: eligibility criteria and first line regimens (revised) Dave le Roux 13 August 2016 Outline Eligibility criteria for starting ART Evolving evidence for earlier ART W Cape, National, WHO

More information

5 Infections. To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and

5 Infections. To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and 5 Infections To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and Southend University Hospital, Antibiotic Guidelines Index 5.1 Antibacterial drugs

More information

1. Procedure for this Invitation to EOI. 2. Medicinal products included on the 14 th Invitation. Guidance Document 14 May 2016

1. Procedure for this Invitation to EOI. 2. Medicinal products included on the 14 th Invitation. Guidance Document 14 May 2016 To support national and global efforts to increase access to and the affordability of HIV/AIDS-related care and treatment together with UNICEF, UNAIDS and UNITAID, invite applicants for selected pharmaceutical

More information

Paediatric ARV Procurement Working Group Progress Review at 31 December 2015

Paediatric ARV Procurement Working Group Progress Review at 31 December 2015 Paediatric ARV Procurement Working Group Progress Review at 31 December 2015 Version 4 March 2015 Updated with complete 2015 data from version presented at the January 27 2016 PAPWG meeting PAPWG Reporting

More information

UNITAID. AMDS Partners Meeting. UNITAID Strategy & 2013 Call for Letters of Intent. Brenda Waning. Page 1

UNITAID. AMDS Partners Meeting. UNITAID Strategy & 2013 Call for Letters of Intent. Brenda Waning. Page 1 Page 1 UNITAID AMDS Partners Meeting UNITAID 2013-2016 Strategy & 2013 Call for Letters of Intent Brenda Waning Geneva 7 May, 2013 UNITAID s Six Strategic Objectives SO1: Increase access to simple, point-of-care

More information

Product Characteristics and Product Information Links between Quality and Clinical

Product Characteristics and Product Information Links between Quality and Clinical Product Characteristics and Product Information Links between Quality and Clinical Regine Lehnert 8th Annual Prequalification Assessment Training (Quality), Copenhagen, 16-18th May 2016 A Good Medicinal

More information

Drug Development by Government Pharmaceutical Organization. Dr. Rachaneekorn Jevprasesphant The Government Pharmaceutical Organization (GPO) Thailand

Drug Development by Government Pharmaceutical Organization. Dr. Rachaneekorn Jevprasesphant The Government Pharmaceutical Organization (GPO) Thailand Drug Development by Government Pharmaceutical Organization Dr. Rachaneekorn Jevprasesphant The Government Pharmaceutical Organization (GPO) Thailand 20August 2012 GPO s Profile GPO was established in 1966.

More information

New Directions on WHO ARV Guidelines 2018

New Directions on WHO ARV Guidelines 2018 New Directions on WHO ARV Guidelines 2018 Elaine Abrams Co-chair WHO Guidelines Development Group ICAP at Columbia University, New York Martina Penazzato Paediatric lead for the HIV Department World Health

More information

hiv/aids Programme Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants

hiv/aids Programme Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants hiv/aids Programme Programmatic update Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants EXECUTIVE SUMMARY April 2012 EXECUTIVE SUMMARY Recent developments

More information

Pneumococcal Vaccine Introductions Dr. Carsten Mantel WHO/FCH/IVB/EPI

Pneumococcal Vaccine Introductions Dr. Carsten Mantel WHO/FCH/IVB/EPI Pneumococcal Vaccine Introductions 2012 Dr. Carsten Mantel WHO/FCH/IVB/EPI Pneumonia is leading cause of death in children < 5 yrs * Pneumococcus and Hib are the two leading causes of life-threatening

More information

Paediatric HIV Resistance. Mohern Archary Paediatric Infectious Diseases Unit King Edward VIII Hospital / University of KwaZulu Natal

Paediatric HIV Resistance. Mohern Archary Paediatric Infectious Diseases Unit King Edward VIII Hospital / University of KwaZulu Natal Paediatric HIV Resistance Mohern Archary Paediatric Infectious Diseases Unit King Edward VIII Hospital / University of KwaZulu Natal Preliminary evaluation of referrals for Antiretroviral Therapy (ART)

More information

UNICEF and the 2030 agenda for Sustainable Development; Focus on Health

UNICEF and the 2030 agenda for Sustainable Development; Focus on Health UNICEF and the 2030 agenda for Sustainable Development; Focus on Health Dr Claudia Vivas Torrealba, Health Specialist cvivas@unicef.org Health Section. Program Division Sep 2016 UNICEF Health Strategy

More information

Caring for sick children in the community: Experiences from Malawi. Humphreys Nsona IMCI Unit

Caring for sick children in the community: Experiences from Malawi. Humphreys Nsona IMCI Unit Caring for sick children in the community: Experiences from Malawi Humphreys Nsona IMCI Unit Outline of the presentation Rationale for community case management of childhood illness (CCM) in Malawi Characteristics

More information

Maternal, Newborn and Child Health: Global initiatives and priority products for MNCH Dr. Mark W. Young Senior Health Specialist, UNICEF-New York

Maternal, Newborn and Child Health: Global initiatives and priority products for MNCH Dr. Mark W. Young Senior Health Specialist, UNICEF-New York Maternal, Newborn and Child Health: Global initiatives and priority products for MNCH Dr. Mark W. Young Senior Health Specialist, UNICEF-New York Copenhagen, Denmark 23 September 2013 Visit www.everywomaneverychild.org

More information

Antibiotic Protocols for Paediatrics Steve Biko Academic Hospital

Antibiotic Protocols for Paediatrics Steve Biko Academic Hospital Antibiotic Protocols for Paediatrics Steve Biko Academic Hospital Respiratory tract infections in children Uncomplicated URTI A child with a cold should not receive an antibiotic Paracetamol (15 mg/kg/dose

More information

Revised National Tuberculosis Control Programme

Revised National Tuberculosis Control Programme Revised National Tuberculosis Control Programme 2015 C e n t r a l T B D i v i s i o n D i r e c t o r a t e G e n e r a l o f H e a l t h S e r v i c e s M i n i s t r y o f H e a l t h & F a m i l y

More information

QUESTIONS AND ANSWERS

QUESTIONS AND ANSWERS QUESTIONS AND ANSWERS Common questions about treating diarrhoea with zinc and oral rehydration salts (ORS) SPACE FOR LOGO INTRODUCTION To treat childhood diarrhoea, the World Health Organization recommends

More information

Objectives. Outline. Section 1: Interaction between HIV and pregnancy. Effects of HIV on Pregnancy. Section 2: Mother-to-Child-Transmission (MTCT)

Objectives. Outline. Section 1: Interaction between HIV and pregnancy. Effects of HIV on Pregnancy. Section 2: Mother-to-Child-Transmission (MTCT) Objectives Prevention of Mother-to-Child Transmission (PMTCT) Teen Club Community Partners Training Programme By the end of the session participants will be able to: 1. Identify factors affecting the transmission

More information

CCC ARV Dosing Recommendations for HIV-exposed infants Updated

CCC ARV Dosing Recommendations for HIV-exposed infants Updated USERS NOTE: Please note this document does not provide guidance on overall decisionmaking regarding what medication(s) to use for HIV-exposed infants. This document is meant to facilitate ARV dosing for

More information

Report of the Informal Expert Meeting on Dosage Forms of Medicines for Children WHO Headquarters, Geneva, Switzerland

Report of the Informal Expert Meeting on Dosage Forms of Medicines for Children WHO Headquarters, Geneva, Switzerland Report of the Informal Expert Meeting on Dosage Forms of Medicines for Children WHO Headquarters, Geneva, Switzerland Comments of the Malta Chamber of Pharmacists 15 th February 2008 The Malta Chamber

More information

Care of the HIV-Exposed Infant

Care of the HIV-Exposed Infant Care of the HIV-Exposed Infant Use of Flipchart To promote quality and consistency of counseling Why use the counseling flipchart? To improve HIV-exposed infant outcomes through high quality counseling.

More information

Management of Tuberculosis Training for Health Facility Staff. F: Manage Drugs and Supplies for TB. WORLD HEALTH ORGANIZATION Geneva

Management of Tuberculosis Training for Health Facility Staff. F: Manage Drugs and Supplies for TB. WORLD HEALTH ORGANIZATION Geneva Management of Tuberculosis Training for Health Facility Staff F: Manage Drugs and Supplies for TB WORLD HEALTH ORGANIZATION Geneva WHO/CDS/TB/2003.314f Management of Tuberculosis Training for Health Facility

More information

Industry Perspective on Formulation and Packaging Considerations

Industry Perspective on Formulation and Packaging Considerations Industry Perspective on Formulation and Packaging Considerations Ron Ogilvie (Pfizer) EFPIA February 2012 1 Industry Perspective on Formulation and Packaging Considerations Provide an overview of formulation

More information

The Global Fund s role as a strategic and responsible investor in HIV/AIDS: Paediatrics and PMTCT

The Global Fund s role as a strategic and responsible investor in HIV/AIDS: Paediatrics and PMTCT The Global Fund s role as a strategic and responsible investor in HIV/AIDS: Paediatrics and PMTCT Peter McDermott Managing Director, CIFF 19 th Board meeting, Geneva 6 th May 2009 Investment Criteria Measurable...change

More information

Nutrition Update Severe acute malnutrition

Nutrition Update Severe acute malnutrition Nutrition Update Assessing the nutritional status of children and the presence of anemia is an integral part of the IMCI ask, look and listen strategy. The risk of death from acute respiratory infection,

More information

INTRODUCTION. WHO/Christopher Black

INTRODUCTION. WHO/Christopher Black INTRODUCTION WHO/Christopher Black 7 1. BACKGROUND In 2016, an estimated 2.1 million children younger than 15 years and 17.8 million women were living with HIV worldwide (1). Despite advances in antenatal

More information

Ministry of Health, Pharmacy Division STOCK STATUS REPORT AS AT NOVEMBER 1st 2013

Ministry of Health, Pharmacy Division STOCK STATUS REPORT AS AT NOVEMBER 1st 2013 istry of Health, Pharmacy Division STOCK STATUS REPORT AS AT NOVEMBER 1st 2013 Introduction The purpose of this report is to inform the istry of Health and all stakeholders of the stock levels in the country

More information

UNICEF/WHO Technical Consultation: IMPROVING ACCESS TO APPROPRIATE PAEDIATRIC ARV FORMULATIONS. November 3-4, WHO Headquarters, Geneva, EB Room

UNICEF/WHO Technical Consultation: IMPROVING ACCESS TO APPROPRIATE PAEDIATRIC ARV FORMULATIONS. November 3-4, WHO Headquarters, Geneva, EB Room UNICEF/WHO Technical Consultation: IMPROVING ACCESS TO APPROPRIATE PAEDIATRIC ARV FORMULATIONS November 3-4, 2004 WHO Headquarters, Geneva, EB Room Summary Background In 2003, more than 5 million people

More information

Technical Guidance Note for Global Fund HIV Proposals. TREATMENT - Antiretroviral Treatment-infants, children and adults

Technical Guidance Note for Global Fund HIV Proposals. TREATMENT - Antiretroviral Treatment-infants, children and adults Technical Guidance Note for Global Fund HIV Proposals TREATMENT - Antiretroviral Treatment-infants, children and adults May 2010 This technical brief is designed to provide key technical information to

More information

Global initiatives and priority products for MNCH

Global initiatives and priority products for MNCH Global initiatives and priority products for MNCH Dr. Mark W. Young Senior Health Specialist, UNICEF-New York Copenhagen, Denmark 22 September 2014 Reductions in absolute numbers of child deaths The total

More information

Prequalification Programme Bioequivalence Assessment Update. Dr. John Gordon

Prequalification Programme Bioequivalence Assessment Update. Dr. John Gordon Prequalification Programme Bioequivalence Assessment Update Dr. John Gordon WHO Prequalification of Medicines Programme 3 rd Meeting with Manufacturers of FPPs and APIs Overview Review of commonly used

More information

APRIL Key Findings: Overall. Key Findings: Availability

APRIL Key Findings: Overall. Key Findings: Availability APRIL 2006 Key Findings: Overall o Medicines were more available in private pharmacies than in other sectors o Even for medicines on the Kenya Essential Drug List, 20 out of 28 of these had below 50% availability

More information

Codeine and Paracetamol in Paediatric use, an Update 5 th October 2013

Codeine and Paracetamol in Paediatric use, an Update 5 th October 2013 Codeine and Paracetamol in Paediatric use, an Update 5 th October 2013 This guidance should be read in parallel to the detailed guidelines on pain management in children (APA guidelines) 2 nd edition.

More information

Category and Product-level Procurement and Delivery Planning Guide

Category and Product-level Procurement and Delivery Planning Guide Category and Product-level Procurement and Delivery Planning Guide Indicative Lead Times 3 July 2018 This document lays out indicative lead-times for planning purposes for key health products for the Global

More information

A Layperson s Guide to Pediatric Formulation Development

A Layperson s Guide to Pediatric Formulation Development A Layperson s Guide to Pediatric Formulation Development Karen C. Thompson PhD Senior Principal Scientist Preclinical Development Merck Research Laboratory West Point, Pennsylvania Martin J. Gartland PhD

More information

Medication Calculations - part 1

Medication Calculations - part 1 Medication Calculations - part 1 Learning Skills Introduction: Common calculations required in nursing include finding volumes needed for oral or injected doses and working out IV infusion flow and drip

More information

Access to essential medicines 59

Access to essential medicines 59 4. 59 4. 4.1 Introduction According to the WHO framework for health systems (1), a well-functioning health system ensures equitable access to essential medical products, vaccines and technologies of assured

More information

WHO/UNICEF JOINT STATEMENT

WHO/UNICEF JOINT STATEMENT WHO/UNICEF JOINT STATEMENT CLINICAL MANAGEMENT OF ACUTE DIARRHOEA Two recent advances in managing diarrhoeal disease newly formulated oral rehydration salts (ORS) containing lower concentrations of glucose

More information

Review of recent changes in WHO and national paediatric care guidelines Dr. Chewe Luo UNICEF New York City, USA

Review of recent changes in WHO and national paediatric care guidelines Dr. Chewe Luo UNICEF New York City, USA Review of recent changes in WHO and national paediatric care guidelines Dr. Chewe Luo UNICEF New York City, USA Review of recent changes in WHO and national paediatric care guidelines Dr. Chewe Luo MMed

More information

Dorothy Mbori-Ngacha UNICEF

Dorothy Mbori-Ngacha UNICEF THE DOUBLE DIVIDEND Action to improve survival of HIV exposed infected and uninfected children in the era of emtct and renewed child survival campaigns Dorothy Mbori-Ngacha UNICEF Outline The Double Dividend

More information

Outline. Aim with PMTCT. How are children transmitted. Prevention of mother-to-child transmission of HIV. How does HIV transmit to children?

Outline. Aim with PMTCT. How are children transmitted. Prevention of mother-to-child transmission of HIV. How does HIV transmit to children? Prevention of mother-to-child transmission of HIV Outline AimofPMTCT How HIV is transmitted to children Epidemiology of HIV in children How to reduce HIV transmission to children Guidelines Lars T. Fadnes

More information

WHO MODEL LIST OF ESSENTIAL MEDICINES APPLICATION

WHO MODEL LIST OF ESSENTIAL MEDICINES APPLICATION Information to be included with an application for inclusion, change or deletion of a medicine in the WHO Model List of Essential Medicines: 1. Name of the focal point in WHO submitting or supporting the

More information